Esperion rises after revenue beat, Q1 profitability expectation

Esperion Therapeutics (NASDAQ:ESPR) shares rose on Tuesday after the company reported second quarter revenue above estimates, and now expects to achieve sustainable profitability beginning in the first quarter of 2026.

The company posted an 11.6% rise in quarterly revenue to $82.39M, beating consensus by $19.34M, as it gained from accelerating clinical adoption of its cholesterol treatments. It also reported a loss of $0.02 per share for the quarter.

"With more than 15% sequential quarterly growth and 42% year-over-year quarterly growth in net U.S. product sales, we are delivering on our commitment to patients and shareholders alike,” stated Sheldon Koenig, CEO of Esperion.

Esperion reiterated its expectation for full year 2025 operating expenses to be in the range of $215M to $235M.

The shares of the company are up about 10% today. YTD, the stock has fallen 25%.